BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36747371)

  • 1. Iris metastasis as resistance mechanism to atezolizumab, carboplatin, and etoposide but responds to additional irinotecan and anlotinib in a small cell lung cancer patient.
    Huang Z; Zhang Y
    Thorac Cancer; 2023 Mar; 14(8):779-782. PubMed ID: 36747371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
    Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
    Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.
    Ishii H; Azuma K; Kawahara A; Matsuo N; Tokito T; Hoshino T
    Invest New Drugs; 2021 Feb; 39(1):269-271. PubMed ID: 32783090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer.
    Kataoka N; Kunimatsu Y; Tachibana Y; Sugimoto T; Sato I; Tani N; Ogura Y; Hirose K; Takeda T
    Thorac Cancer; 2020 Sep; 11(9):2740-2742. PubMed ID: 32706170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.
    Charpidou A; Tsagouli S; Tsimpoukis S; Vassias A; Makrilia N; Stratakos G; Gkiozos I; Syrigos K
    Anticancer Drugs; 2010 Jul; 21(6):651-5. PubMed ID: 20386306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of brain metastases from lung cancer to systemic chemotherapy with carboplatin and etoposide.
    Malacarne P; Santini A; Maestri A
    Oncology; 1996; 53(3):210-3. PubMed ID: 8643223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Wang J; Zhou C; Yao W; Wang Q; Min X; Chen G; Xu X; Li X; Xu F; Fang Y; Yang R; Yu G; Gong Y; Zhao J; Fan Y; Liu Q; Cao L; Yao Y; Liu Y; Li X; Wu J; He Z; Lu K; Jiang L; Hu C; Zhao W; Zhang B; Shi W; Zhang X; Cheng Y;
    Lancet Oncol; 2022 Jun; 23(6):739-747. PubMed ID: 35576956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of anlotinib in combination with standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A multi-center, prospective study (ACTION-2).
    Zhang W; Deng P; Kong T; Zhang B; Qian F; Dong Y; Chen Y; Chen L; Liu D; Zhang Y; Yang H; Han B
    Lung Cancer; 2022 Nov; 173():43-48. PubMed ID: 36116169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer.
    Schmittel A; Fischer von Weikersthal L; Sebastian M; Martus P; Schulze K; Hortig P; Reeb M; Thiel E; Keilholz U
    Ann Oncol; 2006 Apr; 17(4):663-7. PubMed ID: 16423848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
    Lee YC; McCrystal MR; Christmas TI
    N Z Med J; 1998 Nov; 111(1078):451-2, 453-4. PubMed ID: 9891564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective combination chemotherapy of carboplatin and paclitaxel in the treatment of a recurrent small-cell lung cancer patient.
    Kaira K; Ishizuka T; Yanagitani N; Sunaga N; Hisada T; Mori M
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):225-7. PubMed ID: 17301532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.
    Asao T; Watanabe S; Tanaka T; Morita S; Kobayashi K
    BMC Cancer; 2022 Nov; 22(1):1135. PubMed ID: 36333680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy for brain metastases in small-cell lung cancer.
    Chen G; Huynh M; Chen A; Fehrenbacher L; Gandara D; Lau D
    Clin Lung Cancer; 2008 Jan; 9(1):35-8. PubMed ID: 18282356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer.
    Shiono A; Imai H; Wasamoto S; Tsuda T; Nagai Y; Minemura H; Yamada Y; Kishikawa T; Umeda Y; Takechi H; Yamaguchi O; Mouri A; Kaira K; Taniguchi H; Minato K; Kagamu H
    Cancer Med; 2023 Jan; 12(1):73-83. PubMed ID: 35699088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide.
    Reck M; Mok TSK; Mansfield A; De Boer R; Losonczy G; Sugawara S; Dziadziuszko R; Krzakowski M; Smolin A; Hochmair M; Garassino MC; de Castro Junior G; Bischoff H; Lam S; Cardona A; Morris S; Liu SV
    J Thorac Oncol; 2022 Sep; 17(9):1122-1129. PubMed ID: 35764236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.
    Masubuchi K; Imai H; Wasamoto S; Tsuda T; Minemura H; Nagai Y; Yamada Y; Kishikawa T; Umeda Y; Shiono A; Takechi H; Shiihara J; Kaira K; Kanazawa K; Taniguchi H; Kaburagi T; Kagamu H; Minato K
    Thorac Cancer; 2022 Oct; 13(19):2776-2785. PubMed ID: 36062426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Lung cancer with bone metastasis].
    Katakami N
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1049-53. PubMed ID: 16912519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer.
    Bessho A; Ueoka H; Kiura K; Tabata M; Sunami K; Katayama Y; Yamane H; Hiraki A; Harada M
    Anticancer Res; 1999; 19(1B):693-8. PubMed ID: 10216478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
    Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
    Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer.
    Schmittel A; Sebastian M; Fischer von Weikersthal L; Martus P; Gauler TC; Kaufmann C; Hortig P; Fischer JR; Link H; Binder D; Fischer B; Caca K; Eberhardt WE; Keilholz U;
    Ann Oncol; 2011 Aug; 22(8):1798-804. PubMed ID: 21266516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.